Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes

AIM: To investigate the association of different categories of baseline cardio‐metabolic risk factors on the treatment effects of empagliflozin 10 and 25 mg when added as second‐line therapy to metformin in patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Patients aged 18 years or older w...

Descripción completa

Detalles Bibliográficos
Autores principales: Inzucchi, Silvio E., Davies, Melanie J., Khunti, Kamlesh, Trivedi, Prabhav, George, Jyothis T., Zwiener, Isabella, Johansen, Odd Erik, Sattar, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839733/
https://www.ncbi.nlm.nih.gov/pubmed/33084149
http://dx.doi.org/10.1111/dom.14234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839733/
https://www.ncbi.nlm.nih.gov/pubmed/33084149
http://dx.doi.org/10.1111/dom.14234

Ejemplares similares